ANDA 86530, held by Lilly. Secobarbital Sodium.
As of Nov 15, 2026, ANDA 86530 (Seconal Sodium), held by Lilly, was not approved, with 0 approved supplements and 0 published complete response letters.
| Seconal Sodium30MG · suppository;rectal | Secobarbital Sodium | Discontinued |
| Seconal Sodium60MG · suppository;rectal | Secobarbital Sodium | Discontinued |
| Seconal Sodium120MG · suppository;rectal | Secobarbital Sodium | Discontinued |
| Seconal Sodium200MG · suppository;rectal | Secobarbital Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters